Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18708697 | 0.78 | MPO (0.41) | IDO1AGXTRECQLHRH4HTR2C | |
| SCHEMBL10383998 | 0.77 | CA3 (0.43) | IDO1AGXTRECQLHTR2ASLC6A4 | |
| SCHEMBL10383999 | 0.77 | CA3 (0.43) | IDO1AGXTRECQLHTR2ASLC6A4 | |
| SCHEMBL14497956 | 0.76 | RECQL (0.37) | IDO1AGXTRECQLHRH4P2RX7 | |
| SCHEMBL14485293 | 0.74 | GABRA1 (0.36) | IDO1AGXTRECQLHRH4HTR2C | |
| SCHEMBL11914795 | 0.74 | ACE2 (0.41) | RECQL | |
| SCHEMBL25625783 | 0.71 | IDO1 (0.39) | IDO1AGXTRECQLHRH4HTR2A | |
| SCHEMBL5073292 | 0.70 | SLC6A4 (0.47) | HTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22867120 | 0.69 | AGBL2 (0.52) | RECQL | |
| SCHEMBL12197672 | 0.68 | CYP1A2 (0.39) | RECQLHRH4HTR2CHTR2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | IDO1 1973/4885AGXT 668/4885RECQL 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.